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ABSTRACT 
Malaria  continues  to  kill  up  to  3  million  people  each  year,  and  parasite 
resistance to drugs is a pressing problem.  Protein kinases are now prime targets 
for chemotherapy in a variety of diseases such as cancer and neurodegenerative 
diseases,  and  have  been  proposed  as  potential  targets  for  antimalarial 
intervention.    Our  group  is  engaged  in  research  aiming  at  characterising 
Plasmodium  protein  kinases  at  the  biochemical  and  functional  levels,  with 
emphasis on homologues of enzymes that are known regulators of proliferation 
and differentiation in eukaryotic cells. 
The  Mitogen  Activated  Protein  Kinases  (MAPKs)  are  quasi-ubiquitous  in 
eukaryotes, where they play crucial roles in the regulation of cell proliferation 
and  differentiation  in  response  to  extra-or  intracellular  stimuli.    The  MAPKs 
typically function in 3-component modules comprising the MAPK and upstream 
MAPKKs (MEKs) and MAPKKKs (MEKKs).  Surprisingly, experimental and in silico 
analyses  have  demonstrated  P.  falciparum  does  not  possess  any  MEK 
homologues, even though its kinome comprises two members of the MAP kinase 
family.  Prior to the finding that the parasite does not possess MEKs, it had been 
shown in our laboratory that U0126, a MEK inhibitor, had parasitocidal activity in 
vitro.  To confirm and extend these data, a panel of structurally distinct MEK 
inhibitors, most of which are not ATP competitors (and hence are likely to be 
more  selective  than  more  classical  PK  inhibitors)  was  tested  on  cultured  P. 
falciparum.  It is striking that most of the MEK inhibitors kill P. falciparum with 
EC50s that compare very well with those against mammalian cells.  The absence 
of MEK-encoding genes in the Plasmodium genome suggests that the target may 
be a host erythrocyte MEK.  Consistent with this hypothesis, we detected an 
increase of MEK phosphorylation in infected red blood cells (RBCs) compared to 
uninfected  RBCs,  using  a  panel  of  antibodies  directed  against  the  activated, 
phosphorylated  form  of  MEK1.    In  the  presence  of  MEK  inhibitors,  the  signal 
decreased in infected red blood cells.  Furthermore, we show that U0126 does 
not act during invasion or within the first 24 hours of the asexual cycle, but 
during the trophozoite stage.  Taken together, our data strongly suggest that 
infection  with  P.  falciparum  modulates  the  MAP  kinase  pathway  in  its  host 
erythrocyte, and that the parasite relies on this pathway for its own survival.     3 
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1.1 Introduction 
Malaria is a major public health problem in the tropical and sub-tropical regions 
of the world (Fig 1), large areas of Central and South America, Hispaniola (Haiti 
and the Dominican Republic), Africa, the Indian subcontinent, Southeast Asia, 
the Middle East, and Oceania being malaria-risk areas. This disease represents a 
severe burden to socio-economic development of the affected countries.  It is a 
common disease with two billion people potentially at risk and 300 to 500 million 
people infected each year, leading to 1-3 million deaths, mostly among young 
children in sub-Saharan Africa (http://www.rbm.who.int/wmr2005/). 
Malaria  is  caused  by  a  protozoan  parasite  from  the  phylum  Apicomplexa  and 
genus Plasmodium.  There are four species responsible for human malaria [1]: P. 
falciparum,  vivax,  malariae,  and  ovale.    One  of  these,  P.  falciparum, 
predominant in Africa, is responsible for the vast majority of the malaria-related 
deaths. 
1.1.1 P. falciparum life cycle 
Malaria parasites have a life cycle that is split between a vertebrate host and an 
insect vector (Fig 2). 
During  a  blood  meal,  a  malaria-infected  female  Anopheles  spp  mosquito 
inoculates sporozoites into the human host.  Sporozoites infect liver cells and 
mature into schizonts, which rupture and release merozoites.  After this initial 
replication in the liver (exo-erythrocytic schizogony) the merozoites invade red 
blood  cells,  where  they  undergo  asexual  multiplication  (erythrocytic 
schizogony).    During  erythrocyte  invasion  the  parasite  establishes  a 
parasitophorous  vacuole  membrane,  inside  which  it  resides.    It  then  matures 
from the initial ring stage to the trophozoite stage and finally develops into a 
schizont,  the  rupture  of  which  leads  to  the  release  of  up  to  32  merozoites.  
Erythrocytic  schizogony  is  the  stage  of  the  life  cycle  that  is  responsible  for 
malarial pathogenesis.  Instead of undergoing asexual multiplication, and under 
the control of stimuli that are not understood, some parasites withdraw from 
proliferation and differentiate into sexual erythrocytic stages. Audrey Sicard, 2008    Chapter 1, 13 
______________________________________________________________________________ 
 
Figure 1: Geographical distribution of malaria 
Malaria is widespread through the world (South America, Africa, Asia), mostly localized in 
tropical and subtropical regions (in yellow) (http://dpd.cdc.gov/DPDx/HTML/Malaria.htm). 
 
 
Figure 2: Life cycle of Plasmodium falciparum 
(http://dpd.cdc.gov/DPDx/HTML/Malaria.htm) Audrey Sicard, 2008    Chapter 1, 14 
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During  a  blood  meal  a  female  Anopheles  spp  mosquito  can  ingest  male 
(microgametocytes) and female (macrogametocytes) gametocytes, which initiate 
the multiplication of parasites in the mosquito (sporogonic cycle).  While in the 
midgut  of  the  mosquito  the  gametocytes  develop  into  gametes.    The  male 
microgametocytes  undergo  a  process  called  exflagellation,  whereby  eight 
flagellated gametes are formed from every microgametocyte.  Fertilisation of 
the female macrogametocyte then leads to the generation of diploid zygotes.  
The  zygotes  in  turn  develop  into  motile  and  elongated  ookinetes  in  which 
meiotic reduction occurs.  The ookinetes cross the mosquito midgut epithelium 
and become attached to the outer surface of the midgut, where they develop 
into oocysts.  The oocysts, in which intense asexual multiplication occurs, grow.  
Their rupture releases sporozoites, which make their way to the salivary glands 
of  the  mosquito.    Inoculation  of  the  sporozoites  into  a  new  human  host 
reinitiates the life cycle of the parasite. 
1.1.2 Malaria chemotherapy 
Malaria  incidence  has  been  dramatically  reduced  in  some  parts  of  Africa  by 
increasing deployment of anti-mosquito measures [2].  Although a new strategy 
using Insecticide-Treated Net (ITN) might greatly reduce malaria risks, there is 
still a possibility that vector mosquitoes bite outside of peak sleeping hours and 
undermine efficacy of this key malaria prevention measure [3].  Furthermore, 
attempts to develop an effective malaria vaccine have so far failed, because of 
variability of P. falciparum surface proteins [4].  Nevertheless, recent studies 
have  shown  promising  phase  II  results  of  a  trial  to  test  the  efficacy  of 
RTS,S/AS02A vaccine [5].  This vaccine specifically targets the pre-erythrocytic 
stage of P. falciparum and confers protection against infection by P falciparum 
sporozoites.  However, until such a vaccine reaches the market, chemotherapy 
remains  a  major  element  in  the  fight  against  malaria.    Treatments  differ 
according  to  the  infecting  species,  the  geographic  area  where  the  infection 
occurred, and the severity of the disease.  In terms of prophylaxis for travellers 
to malaria-risk areas in South America, Africa, the Indian subcontinent, Asia, and 
the  South  Pacific,  it  is  recommended  to  take  one  of  the  following  drugs: 
mefloquine (Lariam®), doxycycline, or Malarone
TM. Audrey Sicard, 2008    Chapter 1, 15 
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Mefloquine has been found to produce swelling of the Plasmodium falciparum 
food vacuoles.  It is thought act by forming toxic complexes with free heme that 
damage  membranes  and  interact  with  other  plasmodial  components.  
Doxycycline  is  a  member  of  the  tetracycline  antibiotics  group.    It  has  been 
shown  that  tetracyclines  specifically  block  expression  of  the  P.  falciparum 
apicoplast genome [6].  Malarone, a combination of two drugs (atovaquone and 
proguanil) acts at the liver and blood stages.  Atovaquone acts by inhibiting the 
mitochondrial electron transport through the cytochrome c reductase complex 
[7].  To solve resistance problems due to the selection of point mutation in the 
cytochrome c gene, atovaquone was combined with proguanil.  Proguanil acts by 
inhibiting dihydrofolate reductase, an enzyme involved in the sysnthesis of DNA 
precursors. 
Chloroquine (CQ, Aralen®) and Hydroxychloroquine sulfate (Plaquenil®) are also 
greatly used.  Chloroquine (a 4-aminoquinoline drug) enters in the Red Blood 
Cell (RBC) by simple diffusion and prevents formation hemozoin, an insoluble 
form of polymerised heme molecules, leading to heme build up [8].  Chloroquine 
binds to heme, forming a complex.  This complex is highly toxic to the cell and 
disrupts membrane function, resulting in cell lysis and ultimately parasite cell 
autodigestion.    The  mechanism  of  action  of  hydroxychloroquine  sulfate  is 
unknown but may be based on its ability to bind to and alter the properties of 
DNA. It has been found that it could be taken up into the acidic food vacuole of 
the  parasite,  thus  interfering  with  vesicle  functions  and  possibly  inhibiting 
phospholipid metabolism [9].   P. falciparum is widely genetically resistant to 
chloroquine (WHO, 2001) and resistance to chloroquine in P. vivax has increased 
in  South  Asia.    The  best  antimalarial  drug  for  treating  chloroquine-resistant 
malaria parasite remains quinine (or mefloquine and intravenous quinidine) but 
its hypoglycemic effect may be problematic [10].  However, quinine resistance is 
also increasing, especially in Southeast Asia, particularly in the borders areas of 
Thailand  [11].    Chloroquine  has  largely  been  replaced  by  sulfadoxine 
pyrimethamine  (SP)  for  the  treatment  of  P.  falciparum  malaria,  but  there  is 
evidence  that  malaria  parasites  bearing  high-level  pyrimethamine  resistance 
originally arrived in Africa from Southeast Asia [12]. Audrey Sicard, 2008    Chapter 1, 16 
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Despite drug resistance, chemotherapy is currently the only efficient strategy to 
fight against the parasite.  Recently, new antimalarials have been developed, 
such as artemisinin-based combination therapies (ACTs) [13-15].  ACTs combine 
a derivative of the natural product artemisinin, an extremely potent and fast-
acting  antimalarial  endoperoxide,  with  a  longer-lasting  partner  drug  that 
continues to reduce the parasite biomass after the short-lived artemisinin has 
dropped below therapeutic levels [2].  Artemisinin derivatives act rapidly against 
asexual  blood  stage  parasites  to  alleviate  symptoms  and  have  additional 
beneficial  effect  of  killing  gametocytes  and  therefore  decreasing  parasite 
transmission.    Most  countries  in  the  world  have  now  switched  to  an  official 
policy of using an ACT as the first-line treatment [2]. 
The  discovery  of  novel  drugs  having  the  advantages  and  efficacy  that  once 
characterized chloroquine is a high priority for malarial research.  This is why 
novel approaches to antimalarial drug development are reviewed in publications 
[16-18].    A  better  knowledge  of  the  parasite  genome  allows  to  identify  new 
targets.  This is particularly the case for protein kinases (PKs), which represent 
potential drug targets.  In view of their drug ability and proven potential as 
targets  in  a  variety  of  diseases  (see  below),  protein  kinases  represent  an 
attractive class of possible targets for antimalarial intervention [19].  This forms 
the basis of our interest in protein kinases, especially those that regulate cell 
proliferation, such as MAP kinases. 
1.2 MAP kinase pathways 
Proper  regulation  of  genes  in  all  forms  of  cellular  life  is  dependent  on 
intracellular  regulatory  circuits  or  signal  transduction  pathways.    Among 
eukaryotic  cells,  phosphorylation  of  intracellular  factors  followed  by  specific 
gene transcription is an important output of such signal transduction pathways, 
and  the  major  elements  of  many  such  pathways  are  conserved  in  species  as 
different as humans, fungi, and plants.  Across the eukaryotic kingdom, these 
highly  conserved  regulatory  circuits  maintain  the  balanced  gene  transcription 
necessary for correct cell growth, differentiation, and death [20]. Audrey Sicard, 2008    Chapter 1, 17 
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1.2.1 MAP kinase pathways in higher eukaryotes 
1.2.1.1   Regulation of MAP kinases 
The enzymes of the Mitogen-Activated Protein Kinase (MAPK) family are critical 
components  of  a  central  switchboard  that  coordinates  incoming  signals 
generated by a variety of extracellular and intracellular mediators [21-23].  In 
mammalian  cells,  the  MAPK  family  is  an  evolutionarily  conserved  class  of 
proline-directed serine/threonine kinases [24], which include ERK1/2, p38 Hog, 
JNK/SAPK, ERK3, ERK5 and ERK7/8.  Specific phosphorylation and activation of 
enzymes in the MAPK module, which comprises MAPKKKs, MAPKKs MAPKs and 
scaffolding  proteins,  transmits  the  signal  down  the  cascade,  resulting  in  the 
phosphorylation  of  many  proteins  with  substantial  regulatory  functions 
throughout  the  cell,  including  other  protein  kinases,  transcription  factors, 
cytoskeletal proteins and other enzymes (Fig 3). 
This family has been implicated in a number of biological events including cell 
proliferation,  differentiation  and  metabolism.    Activation  of  MAPK  family 
members  involves  the  dual-phosphorylation  of  a  conserved  threonine  and 
tyrosine (TXY) motif located in the activation loop, just before the conserved 
kinase sub-domain VIII “APE” region [25, 26] (Fig 4).  This event is mediated by 
the upstream dual specificity MAPK kinases (MAPKKs, also known as MAP/ERK 
Kinase or MEKs).  MEK isoforms are dual specificity kinases in that they are able 
to phosphorylate tyrosine as well as serine and threonine residues [27, 28].  MEK 
isoforms include: MEK-1, -2, -3, -4, -5, -6, and –7.  Activation of MEK (MEK1/2) 
involves the dual-phosphorylation of the conserved serines (SMANS) motif by a 
MAP/ERK Kinase Kinase (MEKK) such as Raf1 [29] (Fig 4).  Furthermore, it has 
been shown that phosphorylation of a serine localised in position 297 by a PAK1 
(p21-activated  kinase)  stimulates  the  Raf1-dependent  phosphorylation  of  the 
two  serines  localised  in  the  activation  loop  [30].    Activation  of  the  pathway 
occurs in response to elements lying upstream of the MEKK, in response to intra 
or extracellular signals. 
 Audrey Sicard, 2008    Chapter 1, 18 
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Figure 3: Parallel MAP kinases cascades involve specific MAP kinase enzyme modules 
Each of the MAPK/ERK, JNK and p38 cascades consists of a three-enzyme module that 
includes MEKK, MEK and an ERK or MAPK super family member.  A variety of extracellular 
signals trigger initial events upon association with their respective cell surface receptors 
and this signal is then transmitted to the interior of the cell where it activates the 
appropriate cascades.  The shaded area indicates those signalling molecules that become 
associated with the intracellular surface of the plasma membrane upon activation.  
(http://www.promega.com/pnotes/59/5644f/5644f_core.pdf) Audrey Sicard, 2008    Chapter 1, 19 
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Figure 4: Structure of kinases 
A: Primary structure: XI sub-domains (in yellow) of the catalytic domain based on highly 
conserved residues.  The activation of the kinase is due to a dual phosphorylation of 
residues represented in red.  B: Left: Crystal structure of active human ERK2 with ribbons 
colored according to their secondary structure, b b b b-sheets in yellow, a a a a-helices in purple and 
loops in cyan (www.nature.com/onc/journal/v26/n22/fig_tab/1210415f1.html).  Right: Crystal 
structure of inactive MEK1 with ribbons colored according to their secondary structure, b b b b-
sheets in green, a a a a-helices in cyan and loops in brown 
(www.nature.com/nsmb/journal/v11/n12/full/nsmb859.html). 
 
Figure 5: Three-dimensional representations of the ternary complex of PD318088 and 
MgATP bound to human MEK1 
MEK1 protein kinase structure with the N-terminal lobe on top, the C-terminal lobe at the 
bottom and the kinase active site occupied by MgATP and inhibitor located in the hinge 
region. The  -helical regions of the protein are cyan, the  -sheet regions are green, the ATP 
cofactor is pink, the magnesium atom is magenta and PD318088 is gold.  PD318088 is an 
analog of PD184352. 
(http://www.nature.com.gate2.inist.fr/nsmb/journal/v11/n12/full/nsmb859.html) Audrey Sicard, 2008    Chapter 1, 20 
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The ERK signalling module was the first MAP kinase cascade to be characterised, 
being  a  vital  mediator  of  a  number  of  cellular  fates  including  growth, 
proliferation, and survival.  There are two mammalian ERK isoforms that are 
ubiquitously  expressed,  ERK1  and  ERK2,  and  these  are  often  referred  to  as 
p42/p44  MAP  kinases  [31,  32].    In  this  cascade,  MEK1  and  MEK2  function  as 
upstream  MAPKKs  and  the  Raf  proteins  as  MAPKKK.    Duration  of  ERK1/2 
activation depends on regulated removal of one or both phosphates by specific 
tyrosine or serine/threonine phosphatases (MAPK phosphatases), which radically 
decreases ERK activity [33].  Furthermore, the specificity of these phosphatases 
is dependent on their intracellular localisation.  ERK1/2 as well as other MAP 
kinases  target  not  only  transcription  factors  but  also  membrane  proteins  and 
cytoplasmic  proteins.    Gene  knockout  experiments  have  illustrated 
theimportance of the ERK1/2 pathway [28].  Disruption of any of the three Raf 
proteins known to activate ERK1/2 is invariably fatal in mice [28].  Also, when 
MEK1  was  genetically  targeted,  embryonic  death  was  observed  with  signs  of 
tissue necrosis [28]. 
Precisely how ERK1/2 affects cellular physiology in vivo is poorly understood.  
Most often an important role is attributed to ERK1/2 dependent regulation of the 
activating  protein  1  (AP-1)  family  of  transcription  factors.    Members  of  this 
family that are phosphorylated by ERK1/2 include c-Jun, c-Fos, and activating 
transcription factor 2 (ATF-2) but the in vivo relevance of this phosphorylation is 
not yet clear [34]. 
1.2.1.2  MEK inhibitors 
Specific  and  potent  inhibitors  of  MEK1/2  have  been  developed  [35].    By 
screening compound libraries on constitutively active MEK1 recombinant protein, 
the first MEK inhibitors, PD98059 and U0126, were identified [36, 37].  These 
first-generation  MEK  inhibitors  have  been  utilized  extensively  as  tools  to 
elucidate  the  role  of  the  ERK  pathway  in  variety  of  biological  processes.    A 
second-generation MEK inhibitor, with enhanced bioavailibility, PD184352, has 
been synthesized [38].  The majority of protein kinase inhibitors developed so 
far are competitive with ATP and are believed to interact within the ATP-binding  Audrey Sicard, 2008    Chapter 1, 21 
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site of their target protein kinase.  In contrast, PD98059, U0126 and PD184352 
differ in this respect since they are allosteric inhibitors that do not compete 
with ATP [39] (Fig 5).  Such a peculiar characteristic may confer a high level of 
specificity  of  PD98059,  U0126  and  PD184352  towards  MEK1/2;  none  of  these 
compounds  significantly  inhibits the  activity  of  a  large panel  (at  least  24) of 
protein kinases, which includes ERK1, JNK1, and p38 kinases in an in vitro assay 
[40].    The  precise  action  mechanism  of  PD98059,  U0126  and  PD184352  is 
unknown.  However, studies have shown that it seems very likely that PD98059, 
U0126 and PD184352 act similarly as allosteric inhibitors: they bind outside the 
ATP  and  ERK1/2  binding  sites  on  MEK1/2  and  the  modification  of  the  three 
dimensional structure of MEK1/2 renders it not phosphorylatable by upstream 
kinases  [40].    Therefore,  these  inhibitors  do  not  inhibit  MEK  itself,  but  its 
phosphorylation/activation.  Recently another study showed that PD184352 and 
U0126 are extremely potent and selective inhibitors of MEK1/2 [41].  A panel of 
70-80 protein kinases was expressed in different cell lines and kinase assay were 
performed in presence of inhibitors (65 compounds) to determine the efficiency 
of every compound on each protein [41]. 
SL327  (or  MEK  inhibitor  1/2),  which  is  a  water-soluble  structural  homolog  of 
U0126 [37, 42], and other ATP competitor inhibitors of MEK (e.g. MEK Inhibitor I, 
a cell permeable pyridine-containing vinylogous cyanamide compound and MEK 
Inhibitor  II,  also  called  2-Chloro-3-(N-succinimidyl)-1,4-naphthoquinone))  [37, 
43]  have  been  developed  and  are  commercially  available.    These  inhibitors 
display significant affinity only towards ATP-bound MEK.  However, as described 
above, those ATP competitor inhibitors also affect other protein kinases such as 
PKA, PKC and Raf1 at higher concentrations [43] and are therefore less specific 
than the U0126 or PD124352. 
1.2.2 MAP kinases of P. falciparum 
Work in the Doerig laboratory is focussed on signalling pathways that regulate 
cell  proliferation  and  differentiation  in  P.  falciparum.    In  this  context,  two 
plasmodial  members  of  the  MAPK  family  have  been  characterised:  Pfmap-1 
(PF14_0294) [44] and Pfmap-2 (PF11_0147) [45]. Audrey Sicard, 2008    Chapter 1, 22 
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·   Pfmap-1 has a conserved MAPK catalytic domain and a characteristic 
phosphorylation/activation site, TDY, which is used as an activation site by all 
MAPKs characterized so far.  It is not related to classical MAPKs of the ERK1/2, 
p38 or JNK subfamilies, but to ERK7/8, a novel class of MAPK-related enzymes 
[46, 47].  Pfmap-1 is expressed in both asexual stages and gametocytes, but its 
function in parasite development has not yet been determined [45].  However, 
recent  reverse  genetics  studies  show  that  this  gene  is  not  essential  for  the 
parasite and no phenotype has been discovered so far, either on the asexual 
growth, gametocytogenesis or on oocyst and sporozoite formation [48]. 
·  Pfmap-2  is  a  very  atypical  MAPK  that  displays  a  divergent  putative 
activation site (Thr-Ser-His instead of the Thr-X-Tyr that is conserved in all other 
MAPKs).   Phylogenetic  analysis  places Pfmap-2  at the  very base  of  the  MAPK 
cluster  [49],  rendering  orthology  assignment  to  any  known  MAPK  impossible.  
Pfmap-2 is expressed predominantly in gametocytes [45] but the protein can also 
be detected by HA tagging in asexual stages [48].  Inactivating the P. falciparum 
pfmap-2 genomic locus was possible only if an episome expressing the protein 
was present in the transfected parasite, demonstrating that the gene is essential 
for asexual parasite survival [48].  In contrast, the pbmap-2 gene is not essential 
in P. berghei.  When the P. berghei homologue, Pbmap-2, is knocked out, the 
exflagellation of male gametocytes is almost entirely abolished [50-52]. 
Surprisingly, no typical member of the MAPKK was found in the P. falciparum 
kinome [49, 53].  Despite the absence of plasmodial genes clustering within the 
MAPKK family, two sequences were found with around 30% identity to human 
MEK1:  PfPK7  (PFB0605w)  and  PfPK8  (PFB0150c)  (Hanot,  Dorin  &  Doerig, 
unpublished). 
·  PfPK7  displays  34%  identity  to  vertebrate  MAPKK3/6.    MEK-related 
sequences are located in the C-terminal lobe, whereas the N-terminal lobe is 
more closely related to fungal cAMP-dependent protein kinases (PKA).  PfPK7 is 
expressed in several developmental stages of the parasite, both in the mosquito 
vector and in the human host.  It is not strictly essential for erythrocytic asexual 
growth, although both asexual and sexual stages are impaired when this gene is 
knocked out [54]:  PfPK7 KO asexual parasites grow slower than the wild type Audrey Sicard, 2008    Chapter 1, 23 
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and there was no oocysts formation in the mosquito stage, and both phenotypes 
were rescued by complementation with an episome expressing the PfPK7 cDNA.  
Recombinant PfPK7 displayed kinase activity towards a variety of commercial 
substrates,  but  was  unable  to  phosphorylate  the  two  P.  falciparum  MAPK 
homologues  in  vitro,  making  it  unlikely  to  function  as  a  MEK  functional 
homologue. Furthermore, it was insensitive to PKA and MEK inhibitors [29]. 
·  PfPK8 possesses a MAPKK-like protein sequence showing 28% identity in 
the catalytic domain with both Ste20 family kinases, which act upstream of the 
3-component MAPK module [55], and MEKs.  PfPK8 contains a large N-terminal 
extension,  which  includes  repetitive  sequences.    This  gene  product  has  a 
potential phosphorylation site motif “SDQS” with two serine residues in close 
proximity within the activation loop, which is similar to the “SMANS” signature 
of  MEK1/2,  where  the  C-terminal  serine  is  phosphorylated  by  the  upstream 
MEKK. 
However, PfPK8 (like PfPK7, see above) is active in vitro against various non-
physiological substrates, but do not phosphorylate plasmodial or human MAPKs 
and is therefore unlikely to represent MEK functional homologues. 
Another protein, Pfnek-1 (PFL1370w), possesses an activation site reminiscent of 
that found in MEK1/2. 
·  Pfnek-1 displays maximal homology to the never-in-mitosis/Aspergillus 
(NIMA)/NIMA-like  kinase  (Nek)  family  of  protein  kinases,  whose  members  are 
involved  in  eukaryotic  cell  division  processes.    Pfnek-1  possesses  a  large  C-
terminal extension in addition to the catalytic domain, which is very similar to 
many  enzymes  of  the  NIMA/Nek  family.    Surprisingly,  the  FXXT  motif  usually 
found in NIMA/Nek protein kinases is substituted in Pfnek-1 by a SMAHS motif, 
which  is  reminiscent  of  a  MAP/ERK  kinase  (MEK1/2)  activation  site  (SMANS).  
Recombinant Pfnek-1 is able to specifically phosphorylate Pfmap-2 in vitro, and 
that co incubation of Pfnek-1 and Pfmap-2 results in a synergistic increase in 
exogenous  substrate  labelling  [56].    Therefore,  Pfnek-1  may  play  a  role  in 
pfmap-2 regulation in vivo, although this has not been demonstrated. Audrey Sicard, 2008    Chapter 1, 24 
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Taken  together,  experimental  and  in  silico  analyses  demonstrate  that  P. 
falciparum does not possess any typical MEK homologues, and reveal the absence 
of typical 3-component MAPK modules in malaria parasites [29].  Phylogenetic 
analysis  of  the  P.  falciparum  kinome  [49]  independently  confirmed  that  no 
plasmodial sequence clusters within the STE family, which comprises MEKs. 
1.3 PKs as drug targets for cancer 
As mentioned above, reversible phosphorylation of many proteins plays a central 
role in most cellular processes.  In eukaryotic cells about 30% of the proteins 
carry phosphate groups.  Many diseases, such as cancer and neurodegenerative 
diseases, have as an origin a deregulation of protein phosphorylation [57], and 
therefore protein kinases are now considered as promising drug targets.  Indeed, 
the first kinase inhibitor (imatinib mesilate or ST1571, which is a tyrosine like 
kinase inhibitor) to be developed as a drug (Gleevec), has recently been made 
available on the market [58, 59], and a CDK inhibitor is now in clinical trial for 
anti-cancer evaluation [60]. 
The  P.  falciparum  kinome  comprises  approximately  80  protein  kinases  [49].  
Several  of  these  protein  kinases  have  been  characterised,  which  led  the 
observation  that  the  properties  of  these  enzymes  diverge  significantly  from 
those of their mammalian homologues.  Specific inhibition of malarial kinases 
might, therefore, lead to the development of novel antimalarials. 
1.4 Host cell protein kinases as antimalarial drug targets 
There are two reasons for considering host cell proteins as targets in the context 
of chemotherapy against parasitic diseases: 
(i)  The first one is purely scientific: evidence is accumulating that host cells 
are far from passive partners in the interaction with the parasite.  The host cell 
mediates  processes,  which  are  essential  to  parasite  survival.    Targeting  host 
components has the considerable advantage that parasite drug resistance cannot 
result from alterations of the drug target [19]. Audrey Sicard, 2008    Chapter 1, 25 
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(ii)  The second one is economical: the major problem with new antimalarials 
is  the  reluctance  of  the  pharmacological  companies  to  invest  in  expensive 
research  if  the  marketing  prospects  are  poor.    One  solution  to  resolve  this 
situation  would  be  to  identify  a  drug  already  developed  for  other  purposes, 
which  would  have  anti-parasitic  effects.    Additionally,  many  drug  companies 
have large libraries of compounds that been shown to be unfit for their originally 
intended purpose, but may still be attractive as anti-malarials. 
However the question of the toxicity of the compounds on the patient remains.  
Would  a  drug  that  acts  on  the  host  cell  kinase  be  safe  for  the  patient?    As 
mentioned before, protein kinase inhibitors are actually used as drug targets for 
cancer therapy.  In the context of anti-malarial drugs these compounds would be 
required for a short time and therefore toxicity would be a lesser issue than in 
context (such as cancer) where chemotherapy must be used for an extended 
period of time. 
1.4.1 Selected instances of parasite requiring host protein kinase 
activity: 
Some host cell protein kinases or signalling pathways are required for survival of 
intracellular parasitic protists (Table 1). 
1.4.1.1  Theileria 
Theileria  spp.  are  apicomplexan  parasites  that  infect  cattle  and  bear 
considerable  socioeconomic  impact  on  affected  countries.    The  parasite  is 
transmitted by ticks and establishes an infection in cells of the immune system 
(T.  parva  infects  T  and  B  cells,  whereas  T.  annulata  infects  B  cells  and 
monocytes/macrophages).    Infection  of  the  host  cell  results  in  its 
transformation,  and  the  disease  resembles  a  lymphoma  in  many  respects 
(reviewed in [61]).  A notable difference is that transformation is reversible and 
dependent  on  live  parasites:  if  the  parasite  is  killed  by  treatment  with  an 
appropriate drug, the host cell stops proliferating and dies. Audrey Sicard, 2008    Chapter 1, 26 
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Species 
Host cell 
PK/pathway 
Host cell type  References 
Apicomplexa 
Plasmodium falciparum  PKC  Erythrocyte  [62] 
p38 activation  Macrophages  [63] 
Toxoplasma gondii 
NF-kB  Fibroblasts  [64] 
NF-kB 
JNK 
Src 
Theileria spp 
PI3K 
Lymphocytes  Reviewed in [61] 
PI3K  [65] 
Cryptosporidium parvum 
Src 
Epithelial cells 
[66] 
Trypanosomatids 
TGFbR  [67] 
PI3K  [68] 
Ca
2+/PKC  [69] 
Trypanosom cruzi 
ERK1 
Epithelial cells 
[70] 
NF-kB  [71] 
ERK1/2 
JAK2/SSTAT1 
Leishmania donovani 
Ca
2+/PKC 
Macrophages 
Reviewed in [72] 
Table 1: Examples of parasites needing the host cell pathways (adapted from reference 15) Audrey Sicard, 2008    Chapter 1, 27 
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To  stimulate  proliferation,  one  of  the  host  cell  pathways,  the  JNK  pathway 
(which is also a MAPK pathway), is activated in infected cells and this leads to 
the  upregulation  of  the  transcription  factor  AP1  [73].    Another  transcription 
factor  that  is  activated  by  Theileria  infection  is  c-Myc,  in  part  through  the 
stimulation of the JAK2/STAT3  signaling pathway; elevated c-Myc levels have 
been shown to contribute to the prevention of apoptosis of the host cell [74].  
Additionally, the NF-kb pathway is also controlled by the parasite.  Normally, a 
“signalosome”,  constituted  by  intra-cellular  stimuli  or  activated  membrane-
bounds receptors, activates the NF-kB pathway [61].  The IkB inhibitor, which 
sequesters  the  NF-kB  transcription  factor  in  the  cytoplasm,  forms  a  complex 
with  the  IKKs  (kinases,  which  when  activated  by  upstream  effectors, 
phosphorylate  IkB).    Once  the  IKKs  are  activated,  the  IkB  inhibitor  is 
phosphorylated  and  releases  the  active  NF-kB.    This  then  stimulates  the 
expression  of  many  genes  functioning  in  the  control  of  cell  proliferation  and 
survival [61].  Constitutive NF-kB activation is achieved by the parasite, not by 
stimulation of the upstream signaling pathways leading to the IKK kinases, but 
instead by the parasite recruiting large amounts of IkB signalosome complexes at 
its surface.  Hence, it appears that a large proportion of the host cell signaling 
pathways is diverted by the parasite to trigger proliferation [61].  Some of the 
relevant pathways are considered as targets for anti-cancer therapy. 
Interestingly, Theileria is not the only intracellular parasite exploiting the NF-kB 
pathway  of  its  host.    The  apicomplexan  Toxoplasma  gondii  and  the 
phylogenetically  distant  Leishmania  donovani  (a  trypanosomatid),  have  also 
been reported to manipulate the NF-kB pathway of their host cell [71, 75]. 
1.4.1.2   Trypanosoma cruzi 
In  the  trypanosomatid  family,  Trypanosoma  cruzi,  modulates  several  host 
pathways  for its  own  development  [68].    T.  cruzi  is  an  obligate  intracellular 
parasite, causing a chronic debilitating illness, Chagas’ disease, in millions of 
people in Latin America.  The flagellate protozoan is transmissible to humans 
and  other  mammals  mostly  by  hematophagous  assassin  bugs  of  the  subfamily Audrey Sicard, 2008    Chapter 1, 28 
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Triatominae (Family Reduviidae) [68].  T. cruzi infects most cell types, including 
fibroblasts, epithelial cells, endothelial cells, myocytes and macrophages. 
T. cruzi invasion may require activation of specific signaling pathways critical for 
parasite  entry  into  host  cells.    This  hypothesis  is  consistent  with  current 
concepts of cellular invasion by virus and bacteria, which can activate surface 
membrane signaling molecules in their interplay with mammalian host cells [76, 
77].  It has been reported that while T. cruzi attaches to epithelial cells lacking 
signalling transforming growth factor b (TGFb) receptor, the adherent parasites 
cannot penetrate and replicate inside the mutant cells, as they do in parental 
cells.  It is still not exactly known how this pathway would be activated by the 
parasite but it has been hypothesised that the TGFb pathway may be activated 
by  a  factor  secreted  by  infective  trypomastigotes  [67].    Other  studies  have 
shown T. cruzi requires other host cells pathway for its own development, such 
as PI3K (Table 1). 
1.4.2 Malaria and host cell signalling pathways: liver stages 
A number of studies demonstrated that P. berghei, which is widely used as a 
model system to study the liver stage of P. falciparum, also interferes with host 
signalling  pathways  [78-80].    The  entry  of  P.  berghei  sporozoites  into 
hepatocytes is relatively well characterized (little is known about parasite-host 
interactions during later developmental stages of the intracellular parasite) and 
it has been established that the parasite induced expansion of the host cell is an 
important  stress  factor  for  infected  cell.    Cell  stress  is  known  to  trigger 
programmed cell death.  In this context apoptotic markers were examined in 
infected hepatocytes and it has been shown that P. berghei inhibits host cell 
apoptosis  in  the  liver  stage  [78].    The parasite interferes  with the apoptotic 
machinery of the host cell but it is not known how it does so. .  However, a 
recent  study  [79]  revealed  that  CS  outcompetes  NFkB  nuclear  import,  thus 
downregulating the expression of many hepatocyte genes controlled by NFkB. Audrey Sicard, 2008    Chapter 1, 29 
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1.4.3 Malaria and host cell signalling pathways: blood stages 
Even  though  the  mammalian  red  blood  cell  is  inactive  in  terms  of  gene 
expression,  it  is  “not  an  inert  bag  of  hemoglobin  (Hb)”  and  evidence  is 
accumulating for complex signalling networks involving protein phosphorylation 
that regulate, for example, cytoskeleton functions and transporter activity [81].  
It has been shown that there is a variety of active signalling protein kinases 
present in the erythrocyte, such as the TyrKs, Syk and Lyn [82], PKC [83], PKA 
catalytic [84] and regulatory [85] subunits, Casein kinase 2 (CK2) [86], ERK1/2 
(see below) and other signaling molecules, such as cGMP binding proteins [85]. 
It has been known for many years that infection of the red blood cell by malaria 
parasites requires protein phosphorylation within the erythrocyte.  Early studies 
demonstrated  that  invasion  is  blocked  by  staurosporine  [87],  which  may  be 
mediated by protein kinases of either the host cell or the parasite (or both).  
Parasite  entry  is  dependent  on  intra-erythrocytic  levels  of  ATP,  which  is 
indicative of the involvement of host protein phosphorylation.  Furthermore it is 
inseparable  from  a  cAMP-independent  kinase  activity  near  the surface  of  the 
erythrocyte, with spectrin (a component of the sub-membrane cytoskeleton) as 
the probable substrate [88].  Moreover, inside the infected erythrocyte, several 
host  proteins,  such  as  band  4.1  [89],  show  increased  phosphorylation  after 
infection.    Infection  by  P.  falciparum  appears  to  modulate  the  activity  of 
erythrocytic PKC: enzymatic activity is decreased upon infection, although the 
physiological significance of this observation has not yet been established [62].  
More recently, a crucial role for erythrocyte heterotrimeric G proteins and b2-
adregenic receptor in the early stages of infection by the malaria parasite was 
uncovered [90], illustrating the complexity of the signalling events within the 
erythrocyte that the parasite must rely on in order to establish infection.  The 
observation in the same study that b-antagonists and heterotrimeric G-protein 
inhibitory peptides affected infection of mice by P. berghei provides a proof of 
principle  that  interfering  with  host  cell  signalling  is  a  promising  avenue  in 
antimalarial chemotherapy. 
Little  is  known  of  the  requirements  for  host  cell  kinase  activity  once  the 
infection  is  established.    Evidence  is  accumulating  that  the  parasite  exports Audrey Sicard, 2008    Chapter 1, 30 
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protein  kinases  to  the  cytoplasm  and/or  the  membrane  of  the  erythrocyte; 
examples include at least some FIKKs (FIKKS are a novel specific Apicomplexa 
protein kinase family, called on the basis of a conserved motif in sub-domain II) 
[91], a casein kinase 1 activity that is associated with the erythrocyte membrane 
[89], a GSK3 homologue [92], a histidine-rich protein (PfHRP1) that is associated 
with erythrocytic band 3 [93] and an ‘‘orphan’’ kinase that localizes in knobs, 
structures  that  mediate  cytoadherence  of  P.  falciparum-infected  cells  to 
endothelial cells [94].  It is likely that the presence of parasite protein kinases in 
the host cell cytoplasm allows the parasite to subvert host signalling pathways.  
An intriguing example may be the activation of an erythrocyte anion channel by 
P.  falciparum  infection.    The  channel  is  activated  either  by  infection  or  by 
exogenous  PKA,  indicating  that  the  parasite-dependent  activation  is  probably 
mediated by phosphorylation [95].  Interestingly, infection apparently results in 
the degradation of the host cell PKA [96], and it is conceivable that channel 
activation is effected through a protein kinase exported by the parasite.  Very 
recently, it has been shown that overexpression of the regulatory subunit of PKA 
(PfPKA-R) in parasite results in down-regulation of anion conductance [97]. 
1.4.4 A role for host MAPK pathways in erythrocyte infection? 
In the course of investigations in our laboratory aimed at characterizing parasite 
MAPK  pathways,  it  was  demonstrated  that  U0126,  an  inhibitor  that  has  high 
specificity  against  MEK1/2,  was  able  to  prevent  parasite  growth  in  a 
hypoxanthine  incorporation  assay,  with  an  EC50  (2-3mM)  that  compared 
favourably with the EC50 of this molecule in other cellular systems (1-10mM, C.M. 
Doerig and C. Doerig, unpublished).  However, as detailed in the sections above, 
it was eventually demonstrated that the parasite does not possess 3-component 
MAPK pathways. 
It could be that the effect of U0126 on parasite growth is due to the inhibition of 
some parasite enzyme, but this is unlikely, because (i) U0126 is an allosteric 
inhibitor that does not target the ATP-binding site but the interaction between 
the MEK and the upstream MEKK, which presumably reduces the problem of lack 
of selectivity, and (ii) the parasite kinases with maximal homology to the MEKs, 
PfPK7, and Pfnek-1, are not affected by U0126 (see above).  Another possibility Audrey Sicard, 2008    Chapter 1, 31 
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is that the target of the inhibitor is the host cell MAPK pathway.  Indeed, there 
is  evidence  that  ERK1/2  pathways  are  present  in  erythrocytes,  where  they 
regulate the activity of a sodium/proton exchanger [98]. 
1.5 Aims and objectives 
The general objective of this project is to test the hypothesis, suggested by the 
observation that U0126 has parasitocidal activity that the parasite relies on host 
erythrocyte  MAPK  pathways  for  its  own  survival.    In  particular,  we  aim  to 
establish  whether  or  not  P.  falciparum  requires  host  MEK  activity  by  (i) 
determining  whether  inhibition  of  host  erythrocyte  MEKs  using  a  variety  of 
inhibitors (in addition to U0126) affects parasite growth and (ii) analysing the 
effect of infection on the activity of host MEK. 
The specific aims to achieve this are: 
1.  To  test  a  panel  of  MEK  inhibitors  and  determine  their  effect  on  P. 
falciparum growth. 
2.  To determine at which stages the MEK inhibitors act. 
3.  To determine if there is an effect of infection on the host MAPK pathway.    32 
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2.1 P. falciparum culture 
2.1.1 Culture of erythrocytic stages of P. falciparum 
P.  falciparum  (clone  3D7)  was  grown  in  human  erythrocytes  as  described 
previously  [99].    In  brief,  the  parasites  were  grown  at  a  5%  haematocrit  in 
complete  RPMI  1640  medium  (for  5l:  79.45g  RPMI  1640  powder  (Invitrogen), 
0.25g  hypoxanthine  (Sigma),  10g  sodium  bicarbonate  –  NaHCO3,  0.25mg 
gentamycine  sulphate  (VWR  International),  0.5%  w/v  of  Albumax  II-lipid  rich 
bovine  serum  albumin  (Invitrogen),  pH  7.2,  filter-sterilized  and  stored  a  4
oC) 
either  in  25cm
2  (5ml  stocks)  or  75cm
2  (25ml  preparative  cultures)  ventilated 
flasks.  The flasks were kept in a 37
oC incubator with a 5% CO2 atmosphere.  To 
remove serum and leukocytes, the blood (obtained in donation pouches from the 
Blood Transfusion Service, Gartnavel Hospital, Glasgow) was washed three times 
(centrifugation  at  2000g,  5min)  in  RPMI  1640  before  use.    The  medium  was 
changed daily and the parasitaemia (PT) was controlled every day by examining 
Giemsa-stained blood smears (Sigma).  When the PT reached 8-10%, the culture 
was harvested or diluted (usually to 0.5%). 
2.1.2 Synchronisation of cultures 
2.1.2.1   Synchronisation by sorbitol treatment 
This  synchronisation  technique  relies  on  the  fact  that  only  rings  survive 
incubation with sorbitol.  A young stage parasite culture (8% PT rich in rings or 
young  trophozoites)  was  spun  down,  and  the  cells  were  resuspended  in  10 
volumes of 5% sorbitol.  After incubation at room temperature for 10min, the 
cells were washed twice into RPMI 1640 medium and resuspended in complete 
medium. 
2.1.2.2   Synchronisation by Percoll 
This technique separates the different stages of P. falciparum using a density 
gradient.  Four large flasks of asynchronous culture with a high PT (<5%) was 
spun  down  at  600g  for  5min  at  room  temperature.    The  supernatant  was Audrey Sicard, 2008    Chapter 2, 34 
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removed and the pellet was washed twice in simple RPMI.  Then, the pellet was 
resuspended at a 20% haematocrit with complete medium.  7ml of 60% Percoll 
(30ml Percoll + 17ml RPMI + 3ml 10X PBS) were added to 15ml centrifuge tubes.  
Slowly, 2ml of parasites were layered onto the Percoll and the tubes were spun 
at 700g for 10min without using brake.  After spinning, the schizonts and late 
trophozoites formed a distinct reddish/brown band near the top of the Percoll.  
The rings, early trophozoites and uninfected RBC formed the pellet.  Using a 
Pastette the schizont layer was carefully removed into a 50ml tube and washed 
twice in simple RPMI.  The pellet was resuspended in complete medium (e.g. 
5ml) and blood 50% (e.g. 500µL).  A smear was done to check the PT and dilute 
down if necessary. 
2.1.3 Infected RBCs purification by MACS Column 
This technique was used to purify the Infected Red Blood Cells (IRBC) from the 
Uninfected.  The magnetic cell sorting (MACS) technique uses the hemozoin (rich 
in  iron)  contained  in  the  parasite.    The  hemozoin  corresponds  to  the  heme 
polymerization,  generated  from  haemoglobin  degradation  by  the  digestive 
vacuole of P. falciparum [100].  A MACS® Column placed in the magnetic field of 
a MACS Separator creates a high gradient magnetic field strong enough to retain 
cells rich in iron (especially the IRBCs at late trophozoites and schizonts stages).  
First of all, the column was loaded with 10ml of buffer (1X Phosphate Buffered 
Saline (PBS, pH 7.2 from GIBCO), 2mM of EthyleneDiamineTetraceticAcid (EDTA, 
Sigma) and 0.5% of Bovine Serum Albumin (BSA, Sigma)) and left for incubation 
at room temperature at least 5min.  The excess of loaded buffer was eluted and 
the column was rinsed with 50-60ml of buffer.  During this time most of the 
media from four preparative cultures (25ml flasks) was removed and the cells 
were  centrifuged  5min  at  2000g  at  room  temperature.    Cultures  already 
synchronised once using sorbitol can be used and in this case 4-5% of PT at late 
stages is the best.  After centrifugation, the supernatant was removed and cells 
were resuspended to 30ml with buffer.  This P. falciparum culture was flushed 
through the MACS® Column, with a very slow flow through to allow the IRBCs to 
bind the column.  Then the column was washed with 50-60ml of buffer, and the 
IRBCs were eluted out of the magnetic field using 30ml of buffer.  The eluted 
material  was  centrifuged  at  2000g  at  room  temperature  for  5min  and  the Audrey Sicard, 2008    Chapter 2, 35 
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supernatant  removed.    The  cells  were  then  lysed  to  perform  molecular 
experiments. 
2.1.4 Proteins extraction 
After MACS column purification, uninfected and infected RBCs were counted on 
a  hematimetre  and  the  same  number  of  cells  was  taken.    These  cells  were 
sonicated in lysis buffer (20mM Tris pH 7.5, 2mM EthyleneGlycerolTetraceticAcid 
(EGTA), 5mM EDTA, 0.5% Triton X100) with phosphatase inhibitors (30mM sodium 
fluoride (NaF), 40mM bglycerophosphate, 20mM sodium pyrophosphate and 1mM 
sodium  orthovanadate)  and  protease  inhibitors  (1mM  phenylmethylsulfonyl 
fluoride  (PMSF),  3mM  benzamidine,  5mM  pepstatin  A  and  10mM  leupeptin).  
Lysates  were  cleared  by  centrifugation  at  10,000g  for  15min  at  4
oC.    The 
supernatant  was  either  used  directly  to  perform  immunoprecipitation  (IP)  or 
diluted  in  Laemmli  2X  (20%  glycerol,  0.1%  bromophenol  blue,  4%  of  Sodium 
Dodecyl  sulfate  (SDS),  0.1M  Tris-Hydrochloric  acid  (HCl)  pH  6.8,  5%  b-
mercaptoethanol), boiled for 3min and stored at -20
oC. 
2.1.5 Western blots performed by Kinexus 
Samples prepared as described above (2.1.4) were sent to Kinexus (Vancouver, 
Canada).    Kinexus  performed  western  blots  using  phospho-specific  antibodies 
(KCSS  7.0)  for  a  panel  of  human  proteins  and  phospho-protein  levels  were 
quantified by luminescence, which was expressed as counts per minute (CPM). 
2.1.6 Cryopreservation of parasites in liquid nitrogen 
5ml  of  a  5%  PT  culture  (containing  a  high  proportion  of  rings  stages)  were 
centrifuged at 2000g for 5min, and the supernatant was removed.  One packed 
cell  volume  of  deep-freeze  solution  (28%  glycerol,  3%  sorbitol,  0.65%  Sodium 
Chloride  (NaCl))  was  added  drop-wise  to  the  pellet.    Cells  were  then 
resuspended and placed into cryotubes for immediate freezing in liquid nitrogen.  
In order to establish a new culture from a frozen stock, the cryotube was thawed 
and the content transferred to a sterile 15ml tube and the volume measured.  
For each ml of RBCs solution, 0.2 ml of sterile solution A (12% NaCl in distilled Audrey Sicard, 2008    Chapter 2, 36 
______________________________________________________________________________ 
water) was added drop-wise, stirred constantly, and left for 3min.  Secondly, 
10ml of sterile solution B (1.6% NaCl in distilled water) was added to the tube 
drop-wise.  After centrifugation for 5min at 2000g, the RBCs were resuspended 
in 10ml of sterile solution C (0.2% dextrose, 0.9% NaCl in distilled water) added 
drop-wise.  Finally, after another centrifugation, the supernatant was removed 
and discarded.  Cells were resuspended in 5ml of culture medium with fresh 
blood  to  obtain  a  haematocrit  of  5%.    The  culture  was  then  maintained  as 
described above. 
2.1.7 Hypoxanthine incorporation assay 
The EC50 values of the MEK inhibitors were determined by the [3H] hypoxanthine 
incorporation assay [100].  Parasites were exposed to the inhibitors for 48 hours.  
Briefly,  asynchronous  parasites  were  aliquoted  in  96-wells  plate  at  a  0.5% 
parasitaemia  and  5%  haematocrit  in  the  presence  of  inhibitor  (0.04–100mM).  
Labeled  [3H]-hypoxanthine  (0.1mCi/well)  was  added after  24hrs  and the  cells 
were harvested on a filter mat with a cell harvester after 48hrs of exposure.  
Scintillation liquid was added on the filter mat and radioactivity counted using a 
b-scintillation counter (in CPM).  The CPM were then transformed in percentage 
of activity (100% corresponding to the higher counts) and blotted against the log 
[drug concentration].  All assays were carried out using untreated parasites with 
DMSO as controls.  The inhibitors were dissolved in DMSO at stock concentrations 
of 1 or 10mM.  Assays were run twice in triplicates for each inhibitor. 
To  measure  the  hypoxanthine  incorporation  along  the  life  cycle,  tightly 
synchronized  parasites,  using  a  Percoll  gradient,  were  plated  at  3-4% 
parasitaemia (early rings) and 5% haematocrit in the presence of inhibitor at 
EC100  and  labeled  [3H]-hypoxanthine.    The  reaction  was  arrested  by  freezing 
down at –20
oC the wells at every 8 hours.  Then the plate was harvested as 
below and CPM blotted against time (in hours). 
2.1.8 Isobolograms 
Two  drugs  that  produce  overtly  similar  effects  will  sometimes  produce 
exaggerated or diminished effects when used concurrently [101].  A quantitative 
assessment is necessary to distinguish these cases from simply additive action.  Audrey Sicard, 2008    Chapter 2, 37 
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This  distinction  is  based  on  the  classic  pharmacologic  definition  of  additivity 
that, briefly stated, means that each constituent contributes to the effect in 
accord with its own potency.  Accordingly, the relative potency of the agents, 
allows a calculation using dose pairs to determine the equivalent of either agent 
or  the  effect  by  using  the  equivalent  in  the  dose-response  relation  of  the 
reference compound.  The calculation is aided by a popular graph (isobologram) 
that provides a visual assessment of the interaction.  Isobolograms between MEK 
and Src inhibitors (U0126 and PP2 respectively) were performed and analyzed 
using the technique as described [102].  Inhibitors dilutions were prepared for 
the  drug  interaction  experiment  on  the  basis  of  estimated  EC50s.    The 
concentrations  in  these  final  solutions  were  adjusted  to  a  range  between 
approximately 10
-2 and 10
2 times the EC50s of the respective inhibitors, using 
geometric  progressions  with  a  factor  of  4.    These  were  eight  different 
concentrations  for  each  inhibitor.    EC50  of  inhibitor  A  (e.g.  U0126)  was 
determined  against  the  intra-erythrocytic  growth  of  P.  falciparum  at  various 
concentrations,  in  the  presence  of  inhibitor  B  (e.g.  PP2)  and  reciprocally.  
Results were expressed in fraction of EC50: FEC50=1 for inhibitor A in the absence 
of inhibitor B.  The assessment of drug interaction is based on calculation of the 
sum of the fractional inhibitory concentrations (SFECs) at the given IC by the 
formula  (ECx  of  inhibitor  A  in  the  mixture/ECx  of  inhibitor  A  alone)+(ECx  of 
inhibitor B/ECx of inhibitor B alone).  SFECs<1 denote synergism, SFECs£1 and <2 
denote  additive  interaction,  SFECs³2  and  >4  denote  slight  antagonism,  and 
SFECs³4 denote marked antagonism. 
2.1.9 Growth assays in culture 
Tightly synchronized parasites by Percoll (late stages of the life cycle) were kept 
in culture until another cycle was initiated.  When the majority of the culture 
was at the ring stage, the parasitaemia of the culture was estimated by counting 
and diluted to 2% of rings.  200ml of the diluted culture was pipetted into 96 well 
plates and the inhibitor (U0126, PD184352 or 1.5% DMSO for the control) added 
at an EC100 at T0.  Smears were then carried out at different times of the life 
cycle:  T0,  T12,  T30,  T40  and  T48  for  each  well  and  the  parasitaemia  was 
estimated for each stage and at each time by counting 10 fields. Audrey Sicard, 2008    Chapter 2, 38 
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2.2 Molecular methods 
2.2.1 SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis was performed using a 5% stacking gel 
(5% acrylamide, 125mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% ammonium persulfate 
(APS) and 0.001% of N’-tetramethylenediamine (TEMED)) and a 12% resolving gel 
(containing 12% of acrylamide, 375mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS and 
0.001% of TEMED).  Gels were run under standard conditions (80V, 15min; 180V, 
1h30). 
2.2.2 Coomassie staining 
SDS-PAGE were stained in fresh Coomassie stain (for 500ml: 0.5g of Coomassie 
Brilliant Blue G-250, 25ml of acetic acid, 225ml of ethanol and 250ml dH2O) for 
15min at room temperature with gentle agitation.  Then gels were destained in 
Destain solution (for 1l: 100ml of acetic acid, 450ml of methanol and 450ml of 
dH2O) for 1h with gentle agitation and dried. 
2.2.3 Immunoprecipitation experiments 
The total cell lysates were prepared as described in 2.1.4 and precleared as 
follows.  0.25mg of mouse IgG and 20ml (25% v/v) agarose conjugate (Protein A-
Agarose) were added to 1ml of whole cell lysate and the mix incubated at 4
oC 
for 30min.  The beads were then pelleted by centrifugation at 1,000g for 30sec 
at 4
oC.  To 1ml of the above cell lysate, 10ml of primary antibody was added and 
incubated for 1h at 4
oC.  20ml of Protein A-agarose was then added and the tubes 
incubated  at  4
oC  on  a  rocker  platform  for  another  hour.    The  pellet  was 
collected  by  centrifugation  at  1,000g  for  30sec  at  4
oC;  and  the  supernatant 
carefully aspirated and discarded.  The pellet was then washed 4 times with lysis 
buffer with proteases and phosphatases inhibitors.   After the final wash, the 
supernatant  was  aspirated  carefully  and  the  pellet  resuspended  in  20ml  of 
Laemmli 4X.  An aliquot of samples was kept after each step and samples were 
boiled  for  3min,  centrifuged  at  1,000g  for  3min,  and  the  whole  volume  of Audrey Sicard, 2008    Chapter 2, 39 
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supernatant  loaded  onto  a  12%  polyacrylamide  gel  for  Western  blotting  (cf 
2.2.4). 
2.2.4 Western blotting 
Proteins were transferred to a nitrocellulose membrane using a semi-dry transfer 
apparatus (23V, 150mA for 45min, Biorad Trans-Blot® SD semi-dry transfer cell).  
Transfer buffer contained 14.4g/l glycine, 20% methanol and 25mM Tris-HCl pH 
8.3.  The nitrocellulose membrane was blocked one hour at room temperature in 
1X Tris-buffered saline (TBS) containing 0.1% Tween-20 with 5% w/v non-fat dry 
milk.    The  nitrocellulose  membrane  was  then  washed  (3x,  10min)  with  wash 
buffer 1X TBS, 0.5% Tween-20 (TBS/T) and then exposed to the primary antibody 
(1:1000 dilution in blocking buffer) overnight at 4
oC.  The membrane was washed 
again (3x, 10min) with TBS/T and incubated for 1hour at room temperature with 
1:2000 anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody 
(anti-rabbit or anti-mouse).  The membrane was finally washed three times and 
signal developed using the chemiluminescence system (ECL, Perkin-Elmer). 
2.2.5 ImmunoFluorescence Assay (IFA) 
RBCs were fixed using the method described by Tonkin et al [103].  Briefly, cells 
were  settled  onto  a  chamber  previously  coated  with  0.1%  poly-L-lysine  for 
30min.  Then the cells were washed once in PBS and fixed with 4% EM grade 
paraformaldehyde and 0.0075% EM grade glutaraldehyde in PBS for 30min.  Slides 
of fixed cells were washed once in PBS and then permeabilized with 0.1% Triton 
X-100/PBS for 10min.  Slides were washed again in PBS, treated with ~0.1mg/ml 
of sodium borohydride (NaBH4)/PBS for 10min and blocked in 3% BSA/PBS for one 
hour.  Primary antibody (diluted 1:50 for anti phospho-MEK1/2) was then added 
and allowed to bind for a minimum of 1hour in 3% BSA/PBS.  Slides were then 
washed three times in PBS for 10min each to remove excess primary antibody.  
AlexaFluor  goat  anti-rabbit  594  secondary  antibody  (Molecular  Probes)  was 
added at 1:1000 dilution (in 3% BSA/PBS) and allowed to bind for an hour.  Slides 
were washed three times in PBS and mounted in 50% glycerol with 2.5% of 1,4-
diazabicyclo [2,2,2] octane (DABCO, Sigma) and DAPI 1mg/ml.     40 
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3.1 Effect of MEK inhibitors on parasite growth 
3.1.1 Treatment with MEK inhibitors affects parasite growth 
Preliminary  results  obtained  in  the  laboratory  using  the  hypoxanthine 
incorporation assay [100] showed an effect of the MEK inhibitor, U0126, on P. 
falciparum  growth,  with  an  EC50  at  2-3mM.    To  confirm  this  result,  this 
experiment  was  repeated  and  extended  to  include  a  panel  of  additional 
commercially  available  MEK  inhibitors  (Calbiochem,  UK)  (Table  2).    All  MEK 
inhibitors tested showed an effect on P. falciparum growth.  The EC50 value for 
each MEK inhibitor compares very well with EC50 values of the same inhibitors in 
various cellular tests in mammalian cells [37, 40, 42, 104, 105].  Two molecules, 
U0126 and PD184352, show a strong effect on P. falciparum, with EC50 values at 
3mM and 6-7mM respectively, whereas the lowest EC50 they display in mammalian 
systems are 1-10mM and >10mM, respectively (Fig 6).  These inhibitors were used 
to carry out all subsequent experiments. Audrey Sicard, 2008    Chapter 2, 42 
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Table 2: EC50s of different MEK inhibitors tested by hypoxanthine incorporation assays 
 
 
Effect of MEK inhibitors on P. falciparum growth
0
10
20
30
40
50
60
70
80
90
100
110
120
0.01 0.10 1.00 10.00 100.00
Concentration (uM)
%
 
A
c
t
i
v
i
t
y
U0126
PD184352
 
Figure 6: Effect of U0126 and PD184352 on P. falciparum growth 
P.  falciparum  culture  at  a  0.5%  parasitaemia  were  plated  in  presence  of  inhibitors  and 
tritiated  hypoxanthine  (0.1m m m mCi/well)  and  incubated  at  37
oC  for  48  hours.    The  range  of 
concentration is 0.41 to 100m m m mM for U0126 and 0.08 to 20m m m mM for PD184352.  The quantity of 
PD184352  available  was  very  low  so  the  hypoxanthine  incorporation  experiment  was 
performed with a lower concentration (20m m m mM instead of 100m m m mM).  The percentage of activity 
was  determined  by  the  hypoxanthine  incorporated  relative  to  the  uninhibited  controls.  
Assays were run twice in triplicate and error bars correspond to SEM. Audrey Sicard, 2008    Chapter 2, 43 
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3.1.2 Determination of stages affected by MEK inhibitors 
3.1.2.1    Effect of MEK inhibitors on parasitaemia 
Having  secured evidence  that  MEK  inhibitors  affect  parasite  proliferation,  we 
then investigated at which stage(s) of the asexual  cycle these inhibitors act.  
Preliminary experiments were performed using an EC90 dose.  However, by using 
this  concentration,  some  parasites  were  able  to  initiate  a  new  life  cycle.  
Because the results were very difficult to analyse and interpret, the experiment 
was  repeated using  an  EC100  dose  (20mM  for  both  inhibitors).   Parasites  were 
synchronised at the late-trophozoites/schizonts stage using the Percoll method 
(cf 2.1.2.2) and put back in culture.  When the majority of the parasites were at 
the ring stage, the inhibitors (U0126 or PD184352, 20mM, i.e. close to EC100) 
were added (T0) and smears were prepared to measure parasitaemia at different 
times  (hours  post  treatment):  T0,  T12  (ring  stage),  T30  (trophozoites),  T40 
(schizont) and T48 (new ring stage). 
There were no significant differences in the number of early ring stage parasites 
between the control and the treated cultures (T12).  The parasites appeared 
viable and no morphological changes were observed (Fig 7). 
In contrast, at T30 there was a significant difference between the numbers of 
late rings/early trophozoites in the treated cultures, compared to the control 
cultures.  In the presence of PD184352 it was very difficult to differentiate the 
late rings from the early trophozoites, suggesting the parasites treated with this 
inhibitor  were  delayed  in  entering  the  trophozoite  stage.    There  was  a 
significant difference in the number of trophozoites, as well as morphological 
changes, between the inhibitor-treated and the control cells.  The morphological 
aspect of cells treated by PD184352 appeared to be blocked at the late rings-
early  trophozoite  stages.    Normal  mature  trophozoites  fill  the  erythrocyte, 
however, the cells treated with U0126 do not show this morphology, are much 
smaller and displayed a very condensed cellular content (Fig 7A). 
At T40, there was a significant difference in the number of schizonts between 
the treated and untreated cells.  No cells treated with U0126 or PD184352  
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Figure 7: Effect of MEK inhibitors (U0126 and PD184352) on P. falciparum along the life cycle 
A: Giemsa stained parasites at different time of the life cycle treated or not by MEK inhibitors. B: Parasitaemia (PT) at different time for each stage in presence 
of 20m m m mM of MEK inhibitors (U0126 and PD184352). The number of cells has been estimated by counting 10 fields. The experiment was done twice in triplicate. 
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together  with  schizonts,  which  was  to  be  expected  because  it  is  difficult  to 
perfectly  synchronise  P.  falciparum cultures  and the  schizont  stage is  a  very 
short stage of the plasmodial erythrocyte cycle.  Cells treated with U0126 were 
all seen to be at the trophozoite stage at T40, and the majority of them seemed 
blocked at this stage, the parasites appearing very condensed as observed at 
T30.  There was a lot of debris in the culture (probably dead trophozoites) and 
the parasitaemia was very low.  With PD184352, the parasitaemia was not as low 
as with U0126 but the parasites also seemed developmentally blocked, albeit at 
an earlier stage (late rings/early trophozoites).  There were no dead parasites 
observed, as opposed to treated effect of U0126 treatment. 
At T48 a majority of late schizonts with some early rings were observed in the 
control culture.  However, treated cultures produced neither schizonts nor rings.  
The  number  of  trophozoites  decreased  from  T40  for  both  inhibitors,  which 
suggests that the majority of treated parasites had died.  The cells treated by 
PD184352 died slowly than those treated by U0126. 
3.1.2.2    Effect of MEK inhibitors on hypoxanthine incorporation 
Having  established  that  the  MEK  inhibitors  prevent  the  maturation  of 
trophozoites into schizonts, we next wanted to determine whether the block 
occurred prior to or after S-phase.  This was investigated by a hypoxanthine 
incorporation assay.  MEK inhibitors and tritiated hypoxanthine were added to 
synchronised parasites at the ring stage.  Every 8 hours an aliquot of the culture 
was harvested.  After 56 hours, the quantity of hypoxanthine incorporated by 
the infected erythrocyte was estimated as described in 2.1.7.  It appeared there 
were no differences between the control and the treated cells during the first 24 
hours  (Fig  8).    This  part  of  the  life  cycle  corresponds  to  the  ring  stage  and 
correlates  very  well  with  the  parasitaemia  measurements  described  above.  
However, at T24, there was significantly less hypoxanthine incorporated in the 
treated  cells  than  in  the  control.    This  difference  became  more  pronounced 
during the rest of the life cycle.  This indicates that MEK inhibitors interfere with 
parasite  development  before  completion  of  genome  replication,  although 
residual DNA synthesis still occurs in the presence of the compounds (this is not 
the case with other inhibitors we tested - see below). Audrey Sicard, 2008    Chapter 3, 46 
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Figure 8: Hypoxanthine incorporation during P. falciparum life cycle in presence of MEK 
inhibitors (U0126 and PD184352). 
MEK inhibitors (20m m m mM), DMSO control, and tritiated hypoxanthine (0.1m m m mCi/well) were added at 
T0.    The  cells  were  harvested  every  8  hours  and  hypoxanthine  incorporation  was 
determined  by  scintillation.    The  experiment  was  performed  in  triplicate  and  error  bars 
correspond to the SEM. Audrey Sicard, 2008    Chapter 3, 47 
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3.2 Effect of infection on host proteins phosphorylation 
3.2.1 Effect of infection on host protein phosphorylation 
Having  demonstrated  that  MEK  inhibitors do  affect  P.  falciparum  growth,  we 
wanted  to  investigate  whether  there  was  an  effect  of  infection  on 
phosphorylation of host erythrocyte MEKs.  Extracts of infected or uninfected 
erythrocytes, prepared following the description in 2.1.5, were normalized using 
the same number of cells.  They were then sent to a company, KINEXUS, which 
performed  Western  blots  using  a  panel  of  70  antibodies  directed  specifically 
against  the  phosphorylated  form  of  a  variety  of  signalling  proteins.  
Interestingly,  this  analysis  revealed  human  phospho-proteins  in  the  infected 
erythrocytes that were not phosphorylated in the uninfected cells (Table 3). 
The proteins giving a signal only for IRBCs were: CDK1/2 (a cyclin-dependent 
kinase),  Dok2  (an  effector  of  tyrosine  kinase),  eIF2a  (a  translation  initiation 
factor), MEK1 (but only for the site S297, see below), PTEN (a phosphatase) and 
PRAS40 (proline-rich Akt/PKB substrate 40 kDa, a tensin homologue), and Src (a 
membrane bound tyrosine kinase).  Some of these proteins are undoubtedly of 
human origin, but other signals, such as CDK1/2 and eIF2a, may be of parasitic 
origin.  Conversely, some antibodies reacted more strongly with the uninfected 
erythrocyte extract than with infected cell extract: MEK1 (T291 and T385, which 
are not the activation site), MEK2 (T394, which again is not the activation site, 
was targeted) and RSK1/2, a ribosomal S6 kinase 1/2.  Of particular interest to 
us was the observation that an antibody against the phosphorylated (S297) form 
of MEK1 gave a much higher signal in infected red blood cells (IRBCs) than in 
uninfected  erythrocytes  (URBCs)  (Fig  9A).    The  phosphorylated  signal  was 
quantified by luminescence and expressed in CPM (Fig 9B).  This suggested that 
host cell MEK1 is activated upon P. falciparum infection.  However, this antibody 
does  not  recognise  the  serines  (217/221)  of  the  activation  loop  but  another 
serine located at position 297.  Phosphorylation of serine 297 by PAK1 was shown 
to “prime” the enzyme for activation [26].  Focussed on the initial themetic of 
this project, we decided to investigate further this observation and carry on the 
work on the MEK1 protein by looking at the effect of P. falciparum infection on 
MEK1 phosphorylation using different approaches. Audrey Sicard, 2008    Chapter 3, 48 
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Figure 9: Effect of infection on host proteins phosphorylation 
A:  Western-blot on Uninfected RBCs (lane1) versus Infected RBCs (lane 2) blotted with anti 
phospho-MEK1.  B:  Histogram of protein phosphorylation for MEK1, MEK2 and Src.  The 
quantity of phosphorylated protein was determined by luminescence. 
 
 
URBCs  IRBCs 
-  CDK1/2 [T14+Y15] 
-  Dok2 [Y142] 
-  eIF2a [S51] 
-  Erk1 [T202+Y204] 
MEK1 [S297] 
MEK1 [T291] 
MEK1 [T385] 
MEK1 [S297] 
- 
- 
MEK2 [T394]  MEK2 [T394] 
-  PTEN [S380+T382+S385] 
-  PRAS40 [T246] 
RSK1/2 [S221/S227]  - 
-  Src [Y529] 
Table 3: Phosphorylated proteins identified by Kinexus Audrey Sicard, 2008    Chapter 3, 49 
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3.2.2 Effect of infection on MEK phosphorylation 
3.2.2.1    Phosphorylation of the activation site (S217/S221): 
We  first  wanted  to  see  if  the  activation  site  of  the  MEK1/2  protein  was 
phosphorylated using different approaches. 
3.2.2.1.1  Western blot analyses: 
A  western  blot  was  performed  on  URBCs  versus  IRBCs  with  an  antibody 
recognising  the  phosphorylated  serines  217/221  of  MEK1/2  (Fig  10).    The 
expected size is around 45kDa.  No band appeared for the URBCs extract when 
there were a lot of parasitic proteins recognized by the antibody for the IRBCs 
extract.  However, there was a major band at 45kDa, which appeared at the 
same size than the band in the positive control lane.  This suggests the major 
band  recognized  in  IRBCs  extract  correspond  to  the  MEK1/2  protein  and  the 
phosphorylated signal is increased in IRBCs compared to the URBCs. 
3.2.2.1.2  Immunofluorescence analyses: 
Immunofluorescence assay (IFA) was used to confirm results obtained by Western 
blotting.  To enhance our confidence that any signal observed can be assigned to 
phosphorylated  MEK1/2,  parallel  IFAs  were  performed  using  two  antibodies 
against the activated form of MEK1/2 from two different companies (Santa Cruz 
inc, CA, USA and Cell Signaling, MA, USA).  Similar results were obtained with 
both antibodies (Fig 11).  There was no fluorescence observed when the cells 
were  incubated  only  with  secondary  antibody  (negative  control,  not  shown).  
The basal level of MEK phosphorylation was very low in URBCs.  In contrast, and 
IRBCs yielded a robust signal, especially at the late stages.  As a signal for the 
phosphorylated  protein  was  observed,  the  next  step  was  to  check  the  non-
phosphorylated MEK expression in both cells types (uninfected and infected).  So 
IFA was carried out with our anti-MEK1 monoclonal antibody.  Unfortunately, no 
signal  was  observed,  and  information  form  the  supplier  indicated  that  this 
antibody is not suitable to perform IFA. Audrey Sicard, 2008    Chapter 3, 50 
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Figure 10: Effect of infection on phosphorylation of MEK1/2 activation site (Ser 217/221) 
Uninfected RBCs (lane1) versus Infected RBCs (lane 2) blotted with anti phospho-MEK1/2 
(Santa Cruz inc, CA, USA) and positive control (Cell Signaling, MA, USA): Hela cells treated 
with TPA (tetradecanoyl phorbol acetate, 200nM for 15min) (lane3).  TPA treatment activates 
the MAP kinase pathway in Hela cells [106]. 
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Figure 11: ImmunoFluorescence Assay 
Smears from asynchronous P. falciparum cultures were fixed using paraformaldehyde and 
glutaraldehyde  and  incubated  with  anti-phospho  MEK  antibodies  (Ser  217/221)  (supplied 
from Santa Cruz inc, CA, USA and Cell Signaling, MA, USA). Audrey Sicard, 2008    Chapter 3, 51 
______________________________________________________________________________ 
3.2.2.2    Phosphorylation of S297: 
To validate and extend the interesting observation  that the Kinexus antibody 
used  to  detect  MEK1  phosphorylation  gave  a  dramatically  increased  signal  in 
infected (versus uninfected) erythrocytes, we purchased the same antibody and 
performed additional experiments. 
We wanted to reproduce the Kinexus Western blot results (Fig 12A).  A protein at 
approximately  45kDa,  which  is  the  expected  size  for  MEK,  was  detected  in 
positive controls (mouse 3T3 cells treated or not with PDGF) and there was also 
a band at the same size for the URBCs and IRBCs.  The signal was stronger in the 
IRBC  than  in  the  URBC  cell  extract,  confirming  the  results  received  from 
Kinexus.  The identity of the band was verified by probing the same membrane 
with  a  highly  specific  anti-MEK1  monoclonal  antibody  recognising  all  forms 
(phosphorylated or not) of the enzyme (Fig 12B).  As with the phospho-antibody, 
a band was recognized at 45kDa for the positive controls and for the URBCs and 
IRBCs.  Interestingly, this revealed that the total amount of MEK1 is higher in the 
extract from uninfected cells than in the extract from infected cells, despite a 
much  stronger  signal in  the  latter  when the  anti-phospho-MEK1 antibody  was 
used (Fig 12A).  This suggested that the differences in signal were due to an 
increase in phosphorylation. 
However the best experiment to prove the protein recognized by the phospho-
antibody  is  the  human  MEK  was  to  immunoprecipitate  the  MEK  (non-
phosphorylated)  from  total  extracts  in  URBCs  and  IRBCs  and  to  perform  a 
Western blot with the anti-phospho-MEK1 antibody (Fig 13A).  No signal was seen 
with beads incubated with cell extract in the absence of antibody.  For extracts 
(URBCs and IRBCs) incubated with the antibody recognizing non phosphorylated 
MEK1, a band was seen at about 55kDa.  This band corresponded to the mouse 
IgG (heavy chain).  Additionally, there was a signal at 45kDa for the URBCs only.  
The membrane was blotted with the MEK1 antibody (Fig 13B) and the same band 
was recognized.  There was a band at 45kDa for the IRBCs too, but this protein 
was not phosphorylated.  The inability to immunoprecipitate the MEK protein 
and particularly the phosphorylated form was investigated further. Audrey Sicard, 2008    Chapter 3, 52 
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Figure 12: Effect of infection on phosphorylation of MEK S297  
A: Uninfected RBCs (lane1) versus Infected RBCs (lane 2) blotted with anti phospho-MEK1 
(BioSource International, USA) and positive controls (Invitrogen, CA, USA): m3T3 cells non-
treated with PDGF (lane3) and m3T3 cells treated with PDGF (lane 4).  B: Uninfected RBCs 
(lane1) versus Infected RBCs (lane 2) blotted with anti-MEK1 (BioSource International, USA) 
and positive controls m3T3 cells non-treated with PDGF (lane3) and m3T3 cells treated with 
PDGF (lane 4). 
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Figure 13: Immunoprecipitation of human MEK in IRBCs and URBCs followed by Western 
blot using an anti-phospho MEK1 antibody (Ser 297) 
A+B:    Human  MEK1  was  immunoprecipitated  using  anti-MEK1  antibody  (BioSource 
International,  USA)  from  URBCs  and  IRBCs.    Lane1:  URBCs  beads  only,  lane  2:  IRBCs 
beads  only,  lane  3:  URBCs  after  immunoprecipitation,  lane  4:  IRBCs  after 
immunoprecipitation,  lane  5:  positive  control  (m3T3  cells-PDGF),  lane  6:  positive  control 
(m3T3 cells+PDGF).  (A): Western blot was performed using anti phospho-MEK1 antibody 
(BioSource  International,  USA)  and  (B):  Western  blot  was  performed  using  anti  MEK1 
antibody (BioSource International, USA).  C+D:  Protein samples were kept after each step 
of the IP.  Lane 1: URBCs total extract before IP, lane 2: URBCs after pre-clear (using a 
mouse IgG antibody, SIGMA), lane 3: URBCs supernatant after IP, lane 4: IRBCs total extract 
before IP, lane 5: IRBCs after pre-clear (using a mouse IgG antibody, SIGMA), lane 6: IRBCs 
supernatant after IP.  (C): Western blot was performed using anti phospho-MEK1 (Ser 297) 
antibody (BioSource International, USA) and (D): Western blot was performed using anti 
MEK1  antibody  (BioSource  International,  USA).    The  pre-clear  step  reduces  non-specific 
binding to the Protein A agarose beads and to the antibody used to perform the IP. Audrey Sicard, 2008    Chapter 3, 53 
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Total extracts (before immunoprecipitation), extracts incubated with mouse IgG 
and  supernatant  after  incubation  with  anti-MEK1  antibody  were  blotted  with 
phospho anti-MEK1 (Ser 297) antibody (Fig 13C).  A band at 45kDa was observed 
for the total extract from IRBCs only, confirming the results obtained previously.  
A  huge  background  was  observed  for  the extracts  after  pre-clear  as  well  for 
URBCs  than  for  IRBCs  but  no  particular  bands  were  observed  at  45kDa.  
Nevertheless,  from  the  supernatant  kept  after  incubation  with  anti-MEK1 
antibody,  a  band  at  45kDa  was  recognized  by  the  phospho-antibody  in  IRBCs 
only.  The membrane was blotted again with anti-MEK1 antibody (Fig 13D) and 
the same band was recognized.  Taken together, these data suggest that the 
phosphorylated  form  of  MEK  cannot  be  immunoprecipitated  from  IRBCs  (see 
Discussion, p65). 
IFA  were  performed  using  this  phospho  antibody,  but  unfortunately  no 
fluorescence was observed, suggesting the antibody is not suitable to perform 
IFAs experiment. Audrey Sicard, 2008    Chapter 3, 54 
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3.2.3 Inhibitors effect on phosphorylation of MEK activation site 
We  next  wanted  to check  if  the  IFA  signal  obtained  in  IRBCs  using  the  anti-
phospho–MEK1/2 antibody (Ser 217/221) would be decreased, as expected, in 
the presence of MEK inhibitors.  Synchronised cultures were maintained until 
parasites initiated a new erythrocytic cycle and then MEK inhibitors (U0126 and 
PD184352 at 20mM) were added (T0). IFA was performed on cells at T0 and T36 
(we showed earlier [Fig 6] that at T36 the MEK inhibitors have detectable effects 
on parasite development) (Fig 14).  At T0, there were still some late schizonts 
and fluorescence was observed for 96% of RBCs infected with schizonts for the 
control (DMSO), 97% for IRBCs (schizont stage) treated with U0126 and 97% for 
IRBCs (schizonts) treated with PD184352 (Table 4).  The early ring stage present 
on the same slides showed fluorescence in the majority of the IRBCs (Table 4).  
This observation was consistent with previous IFA data, demonstrating that there 
was a higher signal for the IRBCs at the late stages of the life cycle.  It thus 
appears there were no differences at T0, i.e at the time the inhibitors were 
added to the cultures.  At T36, the majority of the control culture was at the 
trophozoite stage, with some schizonts already visible.  Again fluorescence was 
visible  in  IRBCs  at  the  late  stages,  either  late  trophozoites  or  schizonts.  
However, in the presence of MEK inhibitors, the number of fluorescent IRBCs 
decreased considerably relative to controls.  No schizonts were observed in cells 
treated with U0126 or PD184352, confirming the results described in 3.1.2 and 
showing  that  treatment  blocks  schizont  development.    Of  the  trophozoite-
infected cells treated with U0126 only 34% were fluorescent and in these cells 
the  fluorescence  was  dramatically  reduced  (Fig  14).    In  cells  treated  with 
PD184352,  the  number  of  cells  presenting  fluorescence  is  even  lower.    The 
experiment was also performed using URBCs; the number of cells for which there 
was fluorescence in URBCs was very low (Table 4). 
Taken together, this set of data shows that interfering pharmacologically with 
MEK  activation  results,  as  expected,  in  a  significant  decrease  in  the  signal 
obtained with the phospho-specific MEK1/2 antibody (see discussion).  
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Figure 14: Effect of inhibitors on phosphorylation of MEK activation site 
ImmunoFluorescence Assay: smears were made at T0 and T36 from synchronous P. falciparum cultures treated with MEK inhibitors and incubated with anti-
phospho MEK1/2 (Ser217/221) antibodies (Santa Cruz inc, CA, USA), (VP: Visible Phase).  The number of cells presenting fluorescence was counted on 100-cell 
samples (table 4, below).  Since treatment prevents schizont development, there were no schizonts to be observed in the treated cultures at T36 bottom right. 
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Table 4: Percentage of cells presenting fluorescence in presence of MEK inhibitors 
VP DAPI
Anti P-
MEK1/2 Merge VP DAPI
Anti P-
MEK1/2 Merge
T0
T36
Early rings Late schizonts
Late trophozoites Late schizonts
DMSO
U0126
PD184352
DMSO
U0126
PD184352
DMSO
U0126
PD184352
DMSO
U0126
PD184352
VP DAPI
Anti P-
MEK1/2 Merge VP DAPI
Anti P-
MEK1/2 Merge
VP DAPI
Anti P-
MEK1/2 Merge VP DAPI
Anti P-
MEK1/2 Merge
T0
T36
Early rings Late schizonts
Late trophozoites Late schizonts
DMSO
U0126
PD184352
DMSO
U0126
PD184352
DMSO
U0126
PD184352
DMSO
U0126
PD184352
VP DAPI
Anti P-
MEK1/2 Merge VP DAPI
Anti P-
MEK1/2 Merge
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3.3 Effect of a Src inhibitor on parasite proliferation 
It is well established that Src, a membrane-bound tyrosine kinase, can stimulate 
the MAP kinase pathway via different proteins such as Grb2, Sos, Ras and Raf and 
thereby  act  as  an  upstream  element  of  MAP  kinase  pathways.    We  were 
therefore very interested by the observation from the Kinexus experiment that 
Src phosphorylation is higher in infected than in uninfected erythrocytes (Table 
3 and Fig 8). 
We wanted to investigate whether a Src inhibitor would have an effect on P. 
falciparum growth, and, if this were the case, whether the block in parasite 
development would occur at the same stage as the block caused by treatment 
with MEK inhibitors.  A similar approach (
3H hypoxanthine incorporation test) 
was  taken  with  the  Src  inhibitor  (PP2)  as  has  been  with  the  MEK  inhibitors 
described earlier (see Fig 6).  The EC50 value of PP2 is 2mM (Fig 15), which is 
comparable  with  the  EC50  value  of  this  inhibitor  in  various  mammalian  cell 
systems (0.6-18mM, [107, 108]). 
The Src inhibitor appeared to have an effect earlier in the life cycle than the 
MEK  inhibitors  (Fig  16).    At  T12,  the  number  of  rings  was  lower  than  in  the 
control and MEK inhibitor-treated cultures.  At T30, the majority of the cells 
were still at the ring stage.  The parasite life cycle progression hence seemed to 
be blocked at the ring stage, and it was very difficult to differentiate the late 
rings from the early trophozoites.  Furthermore, the morphology of the treated 
cells with the Src inhibitor was completely different than that of cells treated 
with MEK inhibitors.  The parasites treated with Src inhibitor appeared to be 
vacuolated.  The parasitaemia continued to decrease and the parasites never 
progressed beyond the early trophozoite stage. 
There was a significant difference in hypoxanthine incorporation between the 
cells treated by Src inhibitor on one hand, and the control cultures or those 
treated with the MEK inhibitors on the other hand.  Incorporation was extremely 
low and the treated parasites synthesised little or no DNA (Fig 17). Audrey Sicard, 2008    Chapter 3, 57 
______________________________________________________________________________ 
An  isobologram  was  performed  between  MEK  and  Src  inhibitors  to  determine 
whether  or  not  there  was  any  synergy  between  these  two  inhibitors.    This 
experiment  required  large  quantities  of  inhibitors  and  so  was  performed 
between U0126 and PP2 only (the supply of PD184352 was from non-commercial 
source and very limited).  Hypoxanthine incorporation assays were carried out as 
described in 2.1.8.  The EC50 for U0126 was 3mM and 2.1mM for PP2, so the range 
chosen  for  U0126  was  (225-0.014mM)  and  for  PP2  (200-0.0122 mM).    The  EC50 
values were determined for each range and an isobologram was plotted (Fig 18).  
No synergy was detected (see discussion). Audrey Sicard, 2008    Chapter 3, 58 
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Figure 15: Effect of PP2 on P. falciparum growth 
P. falciparum culture at 0.5% of parasitaemia were plated in presence of inhibitor and 
tritiated hypoxanthine (0.1m m m mCi/well) and incubated at 37
oC for 48 hours.  The range of 
concentration is 0.412 to 100m m m mM for PP2.  The percentage of activity was determined by the 
hypoxanthine incorporated relative to the uninhibited controls.  Assays were run twice in 
triplicates and error bars correspond to SEM.  
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Figure 16: Effect of Src inhibitor on P. falciparum along the life cycle compared to MEK inhibitors 
A: Giemsa stained parasites at different time of the life cycle treated or not by MEK or Src inhibitors. B: Parasitaemia at different time for each stage in 
presence of 20m m m mM of MEK inhibitors (U0126 and PD184352) and of Src inhibitor (PP2). The number of cells has been estimated by counting 10 fields. The 
experiment was done twice in triplicate. 
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Figure 17: Hypoxanthine incorporation along P. falciparum life cycle in presence of MEK 
inhibitors (U0126 and PD184352) and Src inhibitor (PP2). 
MEK  inhibitors  (20m m m mM),  Src  inhibitor  (m m m mM),  DMSO  control,  and  tritiated  hypoxanthine 
(0.1m m m mCi/well) were added at T0.  The cells were harvested every 8 hours and hypoxanthine 
incorporation was determined by scintillation.  The experiment was performed in triplicate 
and error bars correspond to the SEM. 
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Figure 18: Isobologram of the interaction between MEK inhibitor (U0126) and Src inhibitor 
(PP2) against P. falciparum at the IC50 
Results were expressed as fraction of EC50: FEC50=1 for MEK inhibitor, U0126, in the 
absence of Src inhibitor, PP2.  The assessment of drug interaction is based on calculation 
of the sum of the fractional inhibitory concentrations (S S S SFECs) at the given IC by the formula 
(ECx of U0126 in the mixture/ECx of U0126 alone)+(ECx of PP2/ECx of PP2 alone).  S S S SFECs<1 
denote synergism, S S S SFECs£ £ £ £1 and <2 denote additive interaction, S S S SFECs³ ³ ³ ³2 and >4 denote 
slight antagonism, and S S S SFECs³ ³ ³ ³4 denote marked antagonism.  Data points below the lines 
connecting the IC50 denote no synergism (S S S SFIC> > > >1).     61 
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4.1 Effect of MEK inhibitors on parasite growth 
Malaria is one of the world’s most important infectious diseases and effective 
drugs are vital to the lives of millions of people. Unfortunately, resistance to 
existing  therapies  is  an  increasing  problem  so  new  strategies  are  urgently 
needed  to  help  control  this  pathogen.    Our  work  suggests  that  the  host  cell 
signalling pathways might represent attractive novel targets. 
As  detailed  in  the  introduction,  P.  falciparum  does  not  possess  any  MEK 
homologues.    However,  we  found  that  MEK  inhibitors  were  able  to  kill  P. 
falciparum, suggesting the parasite might rely on the host MAP kinase pathway 
for its own survival.  All the MEK inhibitors we tested do inhibit P. falciparum 
growth  with  EC50  values  that  compare  very  well  with  those  in  mammalian 
cellular assays.  It appears that the inhibitors do differ in efficiency to inhibit 
MEK activation, which is expected due to their different modes of action. 
(i)  Studies  have  shown  that  U0126,  PD98059  and  PD184352  prevent  MEK1 
phosphorylation [40, 109] and not by targeting the ATP pocket.  Even though 
these three inhibitors prevent parasite growth in a range, which is similar to 
those found in mammalian cells, PD98059 seems to have a lower efficiency than 
the other two.  Indeed, for U0126 and PD184352, the EC50 is lower than 10mM, 
when the EC50 for PD98059 is around 30mM.  This is not surprising because it has 
been  already  hypothesised  that  U0126  and  PD98059  are  both  inhibiting  MEK 
phosphorylation but with a different mode of action.  There is at least one study 
[110] in which a cellular process was inhibited by U0126 but not by PD98059, 
supporting  that  both  inhibitors  may  have  distinct  modes  of  action  in  some 
contexts.  Furthermore, it has been proved PD98059 is actually a compound that 
stops one protein kinase (Raf) from activating another (MEK1) [40].  U0126 and 
PD184352 also exert their effect on cells by suppressing the activation of MEK1, 
and not by blocking its activity [40].  Nevertheless, it is not known where those 
inhibitors bind on the enzyme. 
(ii)  SL327,  is  a  water-soluble  structural  homologue  of  the  specific  MEK1/2 
inhibitor U0126 [37, 42].  Its EC50 on parasite growth is around 25mM.  Although 
this inhibitor is a structural homologue of U0126, its EC50 is different than the Audrey Sicard, 2008    Chapter 4, 63 
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one  found  for  U0126.    Slight  structural  modifications  can  affect  different 
parameters and so the efficiency of the inhibitor on the protein.  However this 
EC50  is  comparable  to  the  range  found  for  mammalian  cells  for  the  same 
inhibitor. 
(iii)  The mechanism of action of the two other MEK inhibitors (MEK Inhibitor I 
and MEK inhibitor II) is not known and they are not commonly used.  No data was 
found in the literature about the efficacy of these inhibitors in cellular systems. 
All the MEK inhibitors we tested have an effect on P. falciparum.  The facts we 
observe (i) an inhibition of P. falciparum growth and (ii), no MEK homologues are 
present in P falciparum, strongly suggest that the host MEK might be involved. 
To determine at what stage(s) of the asexual life cycle the MEK inhibitors act, 
the inhibitors (U0126 or PD184352) were added to tightly synchronized parasites 
at the ring stage.  The parasitaemia was then estimated along the life cycle and 
DNA  synthesis  was  monitored.    Both  techniques  showed  there  were  no 
differences from control cultures during the ring stage.  In contrast, at 24 hours 
a significantly lower number of trophozoites were observed for the cells treated 
with MEK inhibitors and, furthermore, the trophozoite shape was abnormal.  The 
morphology of the cells was slightly different depending on the inhibitor the 
cells  were  treated  with.    These  results  were  confirmed  by  the  hypoxanthine 
incorporation assay.  From T24 until the end of the life cycle, the cells treated 
by  the  inhibitors  compared  to  the  control  incorporated  a  significantly  lower 
quantity  of  hypoxanthine.    This  suggests  the  inhibitors  were  acting  at  the 
trophozoite stage.  We were surprised to observe that parasites in the treated 
cultures display different morphologies depending on which inhibitor was used.  
As both inhibitors prevent MEK phosphorylation, a similar effect on the parasite 
shape was expected.  Similar to PD98059 exerting different effects from those of 
other MEK inhibitors in some systems (see above), it thus appears that U0126 and 
PD184352  may  have  different  mechanisms  of  action.    Finally,  the  treated 
parasites were not able to form schizonts.  An experiment was performed to 
observe the effect of MEK and Src inhibitors on the initiation of a new cycle, by 
adding the inhibitors at the late stages of the life cycle.  This experiment was 
performed  once,  that  is  why  the  results  have  not  been  incorporated  in  the Audrey Sicard, 2008    Chapter 4, 64 
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results section.  In this single experiment, there were no effects on the initiation 
of a new cycle, neither with MEK inhibitors nor Src inhibitors.  This is in line with 
the  absence  of  effect  of  U0126  on  invasion  rate  (H.  Taylor,  personal 
communication). 
4.2 Effect of infection on phosphorylation of host 
proteins 
As described in the results section, human proteins have been found to have a 
higher signal for IRBCs only: CDK1/2, Dok2, eIF2a, MEK1, PTEN, PRAS40 and Src.  
All  these  proteins  are  in  pathways  involved  in  cell  cycle  regulation  and  are 
therefore playing a key role for cancer disease.  Indeed, for the majority of 
them, inhibitors have been found to have an effect on the proliferation and are 
therefore  potential  drug  targets  against  cancer.    However,  some  of  these 
proteins are implicated in processes absent in erythrocytes and we suspect those 
proteins to  be parasitic  and  not human  (e.g.  CDK1/2  and eIF2a).    The other 
proteins have not been studied and we focussed the research on MEK1 and Src. 
We had a particular interest for the MEK1 protein.  On the panel of proteins 
screened by Kinexus, there was no antibody against  the MEK1 activation site 
(Ser217/221).  However, an antibody gave a higher signal for the phosphorylated 
form of the MEK1 at the Serine located at 297.  The phosphorylation of this site 
is necessary for efficient activation of MEK1 [111].  S297 is phosphorylated by 
PAK-1 and this phosphorylation is robustly stimulated during cellular adhesion to 
extracellular  matrix  proteins  [111].    It  has  been  shown  that  the  rapid  and 
efficient activation of MEK and phosphorylation on S297 induced by cell adhesion 
to fibronectin is influenced by FAK and Src signaling [111].  Recently a study 
provided  evidence  that  PAK  phosphorylation  of  MEK1  S297  stimulates  MEK1 
autophosphorylation on the activation loop [30].  The observation of an increase 
of phosphorylation for the MEK S297 and Src Y529 residues suggests there could 
be some synergy between those two kinases and they could even be implicated 
in a same pathway (see 4.4). Audrey Sicard, 2008    Chapter 4, 65 
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4.3 Effect of infection on host MEK phosphorylation 
Having  shown  that  MEK  inhibitors  act  on  parasite  growth  at  the  trophozoite 
stage, it was interesting to look at the effect of P. falciparum infection on the 
MAP kinase pathway. 
It appeared there was an increase of MEK phosphorylation in the infected versus 
uninfected  erythrocytes,  as  showed  by  the  results  from  Kinexus.    The  same 
result  was  found  using  two  different  techniques:  western  blot  and  IFA  on 
synchronised culture at the late stages.  This strongly suggests the increased 
signal corresponds to the MEK protein.  However, when the total form of the 
MEK protein was immunoprecipitated using a highly specific monoclonal antibody 
and blotted with an anti-phospho-MEK antibody, the increased signal previously 
observed  in  the  infected  red  blood cells  extracts  disappeared.   Two  possible 
explanations come to mind:  (i) Either the protein recognized is not the human 
MEK, but a parasite protein with a similar molecular weight.  (ii) Or the protein 
is  the  human  MEK  but  once  phosphorylated  it  becomes  refractory  to 
immunoprecipitation with the MEK1 antibody.  Concerning the first explanation, 
it would be really unlikely that a parasite protein would be inhibited by a panel 
of  structurally  different  MEK  inhibitors  and  would  have  exactly  the  same 
molecular weight than the host protein.  From PlasmoDB alignment, only one 
parasitic protein was found to possess a similar activation site to MEK1: PfNek-1.  
Indeed,  as  detailed  in  the  introduction,  this  protein  has  a  SMAHS  activation 
motif, closely related to the SMANS motif found in MEK1.  However, PfNek-1 
does  not  co-migrate  with  MEK1  and  has  a  molecular  weight  around  110kDa 
whereas the molecular weight of MEK1 is close to 43kDa.  Secondly, it is possible 
the phosphorylated form of the protein interacts with other proteins in such a 
way that the site recognized by the antibody (against the non-phosphorylated 
form) becomes not accessible. 
To link the results found in vivo in the presence of MEK inhibitors with the MEK 
phosphorylation, MEK inhibitors were incubated with infected erythrocytes and 
IFAs  performed  to  determine  whether  the  phosphorylated  MEK  signal  was 
affected.  An important decrease in the IFA signal was detected in erythrocytes Audrey Sicard, 2008    Chapter 4, 66 
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treated with MEK inhibitors.  In URBCs no decrease was observed as no signal 
was detected in absence of inhibitors (Fig 11). 
4.4 Effect of Src inhibitor on MEK phosphorylation 
The Kinexus results showed the MEK protein was not the only protein to be up-
phosphorylated in infected red blood cells; Src protein was up-phosphorylated 
too.    The  effect  of  a  Src  inhibitor  was  tested  on  P.  falciparum  culture  to 
investigate whether MEK and Src inhibitors act at the same development stage.  
Furthermore, to determine whether Src inhibitors synergise with MEK inhibitors, 
an isobologram was performed. 
Concerning P. falciparum growth, there was a significant difference between the 
control and the cells treated by Src inhibitor only 16 hours after the drug was 
added, while an effect from MEK inhibitors appeared only 24 hours after the 
drugs were added.  The quantity of hypoxanthine incorporated did not increase 
along the life cycle.  It appears that the Src inhibitor acts at an earlier stage 
than  the  MEK  inhibitors,  and  that  the  effects  on  parasite  morphology  are 
different  depending  on  the  inhibitors  used.    These  two  experiments 
(parasitaemia of life cycle stages and hypoxanthine incorporation) gave different 
information but correlated very well, confirming the Src and MEK inhibitors do 
not act at the same stage, with the Src inhibitor acting earlier than the MEK 
inhibitors. 
Concerning the isobologram, all the points were out of the square, suggesting 
there were no synergy and even a slight antagonism.  Unfortunately we were not 
in a position to repeat this experiment because of limited available amounts of 
the inhibitors.     67 
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By testing a panel of structurally different MEK inhibitors, we observed a very 
strong inhibition of parasite growth.  Most classical kinase inhibitors are ATP 
competitors.  In contrast, the MEK inhibitors used in this study are allosteric 
inhibitors,  interacting  with  the  protein  outside  the  ATP-binding  cleft.    This 
confers a high level of selectivity to these molecules and supports the hypothesis 
that erythrocyte MEKs are the targets.  The results from Kinexus and our own 
Western  blot concur to  show  MEK phosphorylation is  stimulated  by  infection.  
Overall, results from the pharmacological experiment using a panel of MEK (and 
Src)  inhibitors  and  from  the  immunological  approaches  (WB  and  IFAs)  are 
consistent  with  a  role  for  the  host  cell  signalling  pathway  in  erythrocyte 
infection  by  P.  falciparum.    It  will  be  interesting  to  investigate  further  and 
characterise  the  pathway  that  leads  to  MEK  activation,  and  the  downstream 
effectors that are required for parasite survival.  Preliminary data suggest the 
human ERK is not phosphorylated by infection-activated MEK (data not shown).  
Perhaps the parasite is using the host MEK to phosphorylate proteins of parasite 
origin.    The  Kinexus  analysis  revealed  that  Src  is  activated  too  upon  P. 
falciparum infection, and we showed that treatment with a Src inhibitor is lethal 
to the parasite; however, we cannot exclude at this stage that the parasitocidal 
effects of the Src inhibitor are mediated through other (host cell or parasite) 
targets. 
Our discovery that MEK inhibitors prevent parasite development has important 
implications in the context of antimalarial drug discovery, because it suggests 
that host cell pathways represent potential targets.  Indeed, by targeting a host 
protein to kill P. falciparum, the resistance problem, which emerged years ago 
with chloroquine and other treatments, would probably be slower to appear, 
because  the  most  direct  mechanism  to  develop  resistance,  i.e.  selection  of 
parasites expressing mutated target unable to bind to the drug, would not be 
available.  Furthermore, the cost to develop a new drug is huge and as detailed 
in the introduction, inhibitors targeting human kinases (including those in the 
MAPK  pathways)  are  already  in  the  drug  development  pipe-line  for  cancer, 
diabetes or neurodegenerative disorders.  It would be of tremendous economic 
interest to piggy-back on those molecules, for which significant investment has 
already been done.  Finally, this study can be repeated for every protein found 
to have a higher signal for the IRBCs only by Kinexus.     69 
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